AP3237A - 1'-Substituted carba-nucleoside analogs for antiviral treatment - Google Patents
1'-Substituted carba-nucleoside analogs for antiviral treatmentInfo
- Publication number
- AP3237A AP3237A AP2010005414A AP2010005414A AP3237A AP 3237 A AP3237 A AP 3237A AP 2010005414 A AP2010005414 A AP 2010005414A AP 2010005414 A AP2010005414 A AP 2010005414A AP 3237 A AP3237 A AP 3237A
- Authority
- AP
- ARIPO
- Prior art keywords
- nucleoside analogs
- antiviral treatment
- substituted carba
- carba
- substituted
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4726308P | 2008-04-23 | 2008-04-23 | |
US13944908P | 2008-12-19 | 2008-12-19 | |
PCT/US2009/041447 WO2009132135A1 (en) | 2008-04-23 | 2009-04-22 | 1' -substituted carba-nucleoside analogs for antiviral treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2010005414A0 AP2010005414A0 (en) | 2010-10-31 |
AP3237A true AP3237A (en) | 2015-04-30 |
Family
ID=40887058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2010005439A AP3076A (en) | 2008-04-23 | 2009-04-22 | Carba-nucleoside analogs for antiviral treatment |
AP2010005414A AP3237A (en) | 2008-04-23 | 2009-04-22 | 1'-Substituted carba-nucleoside analogs for antiviral treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2010005439A AP3076A (en) | 2008-04-23 | 2009-04-22 | Carba-nucleoside analogs for antiviral treatment |
Country Status (33)
Country | Link |
---|---|
US (5) | US8008264B2 (tr) |
EP (3) | EP2937350B9 (tr) |
JP (4) | JP5425187B2 (tr) |
KR (3) | KR101645742B1 (tr) |
CN (3) | CN102046626A (tr) |
AP (2) | AP3076A (tr) |
AR (1) | AR071395A1 (tr) |
AU (2) | AU2009240642B2 (tr) |
BR (2) | BRPI0911410A2 (tr) |
CA (2) | CA2722177C (tr) |
CO (2) | CO6321235A2 (tr) |
CY (4) | CY1113647T1 (tr) |
DK (3) | DK2268642T3 (tr) |
EA (2) | EA019883B1 (tr) |
EC (2) | ECSP10010609A (tr) |
ES (3) | ES2665272T3 (tr) |
HK (3) | HK1152709A1 (tr) |
HR (3) | HRP20130048T1 (tr) |
HU (3) | HUE025528T2 (tr) |
IL (2) | IL208515A (tr) |
LT (2) | LT2937350T (tr) |
LU (1) | LUC00193I2 (tr) |
ME (1) | ME03089B (tr) |
MX (2) | MX2010011661A (tr) |
NO (1) | NO2937350T3 (tr) |
NZ (2) | NZ588400A (tr) |
PL (3) | PL2268642T3 (tr) |
PT (3) | PT2937350T (tr) |
RS (2) | RS54008B1 (tr) |
SI (3) | SI2280973T1 (tr) |
TW (2) | TW201334784A (tr) |
WO (2) | WO2009132135A1 (tr) |
ZA (2) | ZA201007713B (tr) |
Families Citing this family (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (zh) | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
BRPI0911410A2 (pt) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | análogos de carba-nucleosídeo para tratamento antiviral |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
RS53347B (en) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | TOLL-SIMILAR RECEPTOR MODULATORS |
BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
DK2480559T3 (da) | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
ES2614651T3 (es) * | 2009-09-21 | 2017-06-01 | Gilead Sciences, Inc. | Análogos de carbanucleósido 2' -fluorosustituidos para tratamiento antiviral |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
AU2010311511B2 (en) | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
PT2752422T (pt) * | 2010-03-31 | 2017-11-07 | Gilead Pharmasset Llc | Síntese estereosseletiva de princípios ativos contendo fósforo |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
NZ606141A (en) * | 2010-07-19 | 2015-03-27 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
NZ606156A (en) * | 2010-07-22 | 2015-01-30 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
TW201305185A (zh) * | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
PE20230684A1 (es) * | 2010-09-20 | 2023-04-21 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa |
EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
EP2654900A1 (en) * | 2010-12-20 | 2013-10-30 | Gilead Sciences, Inc. | Combinations for treating hcv |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
US8877744B2 (en) * | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
WO2012142093A2 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9061041B2 (en) * | 2011-04-13 | 2015-06-23 | Merck Sharp & Dohme Corp. | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
US9408863B2 (en) | 2011-07-13 | 2016-08-09 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
EP2731434A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
AP2014007575A0 (en) | 2011-09-16 | 2012-04-30 | Gilead Pharmasset Llc | Methods for treating HCV |
SG11201401082XA (en) * | 2011-09-30 | 2014-04-28 | Kineta Inc | Anti-viral compounds |
AR089650A1 (es) | 2011-10-14 | 2014-09-10 | Idenix Pharmaceuticals Inc | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales |
TWI532485B (zh) * | 2011-10-21 | 2016-05-11 | 艾伯維有限公司 | 治療c型肝炎病毒(hcv)的方法 |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
EP3351552B1 (en) * | 2012-03-13 | 2021-05-19 | Gilead Sciences, Inc. | 2'-substituted carba-nucleoside analogs for antiviral treatment |
MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
EP2852605B1 (en) * | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
EP2869822B1 (en) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Inhibitors of phosphodiesterase 10 enzyme |
WO2014035140A2 (en) * | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
WO2014042433A2 (en) * | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
WO2014052638A1 (en) * | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
MX353422B (es) | 2012-10-08 | 2018-01-12 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloronucleósido para infección por vhc. |
WO2014059902A1 (en) * | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
WO2014059901A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
RU2015123641A (ru) | 2012-11-19 | 2017-01-10 | Мерк Шарп И Доум Корп. | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
US20170198005A1 (en) * | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
US10526363B2 (en) | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体モジュレーターの固体形態 |
TWI740546B (zh) * | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
CA2966033A1 (en) * | 2014-10-31 | 2016-05-06 | Cocrystal Pharma, Inc. | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
EP3233878A4 (en) | 2014-12-15 | 2019-02-20 | Emory University | PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
EA039561B1 (ru) * | 2015-01-20 | 2022-02-10 | Джилид Сайэнс, Инк. | Соединения для лечения вирусных инфекций filoviridae |
GEP20237502B (en) | 2015-03-06 | 2023-04-25 | Atea Pharmaceuticals Inc | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
WO2016160646A1 (en) | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
EP3288957A4 (en) | 2015-05-01 | 2019-01-23 | Cocrystal Pharma, Inc. | NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER |
JP6806709B2 (ja) * | 2015-05-12 | 2021-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン |
DK3331894T3 (da) | 2015-08-05 | 2021-03-22 | Metro Int Biotech Llc | Nicotinamidmononukleotidderivater og anvendelser deraf |
EP3349758B1 (en) * | 2015-09-16 | 2022-04-06 | Gilead Sciences, Inc. | Methods for treating arenaviridae virus infections |
US10953029B2 (en) | 2015-09-23 | 2021-03-23 | Merck Sharp & Dohme Corp. | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
US10745427B2 (en) | 2016-03-09 | 2020-08-18 | Janssen Biopharma, Inc. | Acyclic antivirals |
US9981975B2 (en) | 2016-03-28 | 2018-05-29 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
WO2017184668A1 (en) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
CA3029315A1 (en) | 2016-06-24 | 2017-12-28 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
EP3497111A2 (en) * | 2016-08-12 | 2019-06-19 | Janssen BioPharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN116036114A (zh) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
WO2018129039A1 (en) | 2017-01-04 | 2018-07-12 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
WO2018169946A1 (en) | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
TWI624264B (zh) * | 2017-08-11 | 2018-05-21 | 景鑫生物科技股份有限公司 | 南洋山蘇水萃物的用途 |
MX2020002925A (es) | 2017-09-18 | 2020-10-05 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos. |
BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
EP3732180A4 (en) * | 2017-12-27 | 2022-05-11 | Emory University | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID CELL SPECIFIC ANTIVIRAL AGENTS |
KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
EP3966222A4 (en) | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
CN110724174B (zh) * | 2019-09-10 | 2021-02-05 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪类化合物、组合物及其应用 |
KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
CN113214334A (zh) * | 2020-02-05 | 2021-08-06 | 华创合成制药股份有限公司 | 用于治疗病毒感染的化合物及其制备方法和用途 |
CN113214262B (zh) * | 2020-02-05 | 2023-07-07 | 华创合成制药股份有限公司 | 一种含有胍基的化合物及其制备方法和用途 |
US12030903B2 (en) | 2020-02-18 | 2024-07-09 | Gilead Sciences, Inc. | Antiviral compounds |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
TWI791193B (zh) | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN113292565B (zh) * | 2020-02-24 | 2023-01-31 | 浙江森科建设有限公司 | 核苷类化合物及其制备方法和应用 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN111269248A (zh) * | 2020-03-05 | 2020-06-12 | 江苏福瑞康泰药业有限公司 | 一种核苷氨基磷酸酯类药物母液回收的新方法 |
JP2023516087A (ja) | 2020-03-12 | 2023-04-17 | ギリアード サイエンシーズ, インコーポレイテッド | 1’-シアノヌクレオシドを調製する方法 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP4125810A1 (en) | 2020-03-22 | 2023-02-08 | InspirMed Corp. | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases |
WO2021202669A2 (en) | 2020-04-01 | 2021-10-07 | Reyoung Corporation | Nucleoside and nucleotide conjugate compounds and uses thereof |
WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
AU2021281351A1 (en) | 2020-05-29 | 2023-01-19 | Gilead Sciences, Inc. | Remdesivir treatment methods |
MX2022016405A (es) | 2020-06-24 | 2023-01-30 | Gilead Sciences Inc | Análogos de nucleósido de 1¿-ciano y usos de estos. |
CA3185450A1 (en) | 2020-08-06 | 2022-02-10 | Istvan Borza | Remdesivir intermediates |
CN111956630A (zh) * | 2020-08-20 | 2020-11-20 | 大连理工大学 | 一种瑞德西韦供雾化器用的液体制剂、制备方法及其应用 |
TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022098371A1 (en) * | 2020-11-09 | 2022-05-12 | Yan Matthew | Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
CN112494500B (zh) * | 2020-11-26 | 2022-01-11 | 北京箭牧科技有限公司 | 瑞德西韦在制备治疗抗肿瘤药物心脏毒性药物中的应用 |
CN114621229B (zh) * | 2020-12-11 | 2024-07-02 | 嘉兴金派特生物科技有限公司 | 治疗或预防猫传染性腹膜炎的化合物或组合物 |
CN112592348B (zh) * | 2020-12-21 | 2022-03-08 | 南京法恩化学有限公司 | 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法 |
CN117777141A (zh) * | 2020-12-30 | 2024-03-29 | 南方科技大学 | 一种抗病毒感染的核苷类化合物及其用途 |
JP2024512771A (ja) | 2021-04-16 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
KR20230001208A (ko) | 2021-06-28 | 2023-01-04 | 동아대학교 산학협력단 | 오각고리 염기를 포함하는 비고리형 핵산 모방체 |
CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
AU2022401696A1 (en) | 2021-12-03 | 2024-05-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
CN118369316A (zh) | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
AU2022399845A1 (en) | 2021-12-03 | 2024-05-23 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
CN114437159B (zh) * | 2022-04-11 | 2022-06-28 | 佛山市晨康生物科技有限公司 | 一种环状碳酸酯核苷类化合物及其应用 |
WO2023207942A1 (zh) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | 用于治疗或预防冠状病毒感染的核苷类药物及其用途 |
WO2024006461A1 (en) * | 2022-06-30 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
WO2024088183A1 (en) * | 2022-10-23 | 2024-05-02 | Shanghai Curegene Pharmaceutical Co., Ltd. | Anticoronviral compounds and compositions and uses thereof |
WO2024088184A1 (en) * | 2022-10-23 | 2024-05-02 | Shanghai Curegene Pharmaceutical Co., Ltd. | Anti-feline-coronavirus compounds and uses thereof |
CN115819423A (zh) * | 2022-11-29 | 2023-03-21 | 武汉大学 | 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用 |
CN116217621B (zh) * | 2023-04-26 | 2023-08-11 | 北京沐华生物科技有限责任公司 | 一种核苷类双前药、合成方法及应用 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
JPS59141856A (ja) | 1983-02-02 | 1984-08-14 | Fuji Electric Co Ltd | Fs変復調方式 |
US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
DE10399025I2 (de) * | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
US6887707B2 (en) | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
EP1121361B1 (en) | 1998-10-16 | 2007-08-29 | Merck Sharp & Dohme Limited | Pyrazolo-triazine derivatives as ligands for gaba receptors |
DE19912636A1 (de) * | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
US6656915B1 (en) | 1999-09-15 | 2003-12-02 | Biocryst Pharmaceuticals, Inc. | Inhibiting T-cell proliferation |
WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
EA200200778A1 (ru) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ) |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (zh) | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
MY134070A (en) | 2001-01-22 | 2007-11-30 | Isis Pharmaceuticals Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP2005536440A (ja) | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
US7285658B2 (en) | 2002-02-28 | 2007-10-23 | Biota, Inc. | Nucleotide mimics and their prodrugs |
US20040023901A1 (en) | 2002-02-28 | 2004-02-05 | Cook Phillip D. | Nucleoside 5'-monophosphate mimics and their prodrugs |
US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
RU2004135392A (ru) * | 2002-05-06 | 2005-06-27 | Дженелэбс Текнолоджиз, Инк. (Us) | Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с |
US20050250728A1 (en) | 2002-05-23 | 2005-11-10 | Shanta Bantia | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
EP1658302B1 (en) | 2003-07-25 | 2010-08-25 | IDENIX Pharmaceuticals, Inc. | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
ATE486883T1 (de) | 2003-08-27 | 2010-11-15 | Biota Scient Management | Neue tricyclische nukleoside oder nukleotide als therapeutische mittel |
WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CN101043893A (zh) | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
EP1804812A4 (en) | 2004-10-21 | 2009-09-02 | Merck & Co Inc | FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS |
JP5089395B2 (ja) | 2004-10-29 | 2012-12-05 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | 治療用フロピリミジンおよびチエノピリミジン |
AU2006222563A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
WO2006104945A2 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Hepatitis c therapies |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
CA2665370A1 (en) | 2005-10-03 | 2007-04-12 | University Health Network | Odcase inhibitors for the treatment of malaria |
EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
AU2006320440B2 (en) | 2005-12-02 | 2012-04-05 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
WO2007097991A2 (en) | 2006-02-16 | 2007-08-30 | Pharmasset, Inc. | Methods and kits for dosing of antiviral agents |
AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
WO2008005542A2 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
WO2008033466A2 (en) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
ITBO20060683A1 (it) | 2006-10-03 | 2008-04-04 | Sympak Corazza S P A | Dispositivo per il raggruppamento di confezioni. |
JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
EP2124555B1 (en) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
ES2390188T3 (es) | 2007-01-12 | 2012-11-07 | Biocryst Pharmaceuticals, Inc. | Análogos de nucleósidos antivirales |
WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
CA2685520A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
BRPI0911410A2 (pt) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | análogos de carba-nucleosídeo para tratamento antiviral |
WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
MX2011008409A (es) | 2009-02-10 | 2011-10-21 | Gilead Sciences Inc | Análogos de carba-nucléosido para tratamiento antiviral. |
NZ595590A (en) | 2009-03-24 | 2013-11-29 | Biocryst Pharm Inc | Useful pharmaceutical salts of 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
DK2480559T3 (da) | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
ES2614651T3 (es) | 2009-09-21 | 2017-06-01 | Gilead Sciences, Inc. | Análogos de carbanucleósido 2' -fluorosustituidos para tratamiento antiviral |
EP3290428B1 (en) | 2010-03-31 | 2021-10-13 | Gilead Pharmasset LLC | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
NZ606141A (en) | 2010-07-19 | 2015-03-27 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
NZ606156A (en) | 2010-07-22 | 2015-01-30 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
PE20230684A1 (es) | 2010-09-20 | 2023-04-21 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa |
SI2627334T1 (sl) | 2010-10-15 | 2015-08-31 | Biocryst Pharmaceuticals, Inc. | Sestavki za uporabo pri zdravljenju virusnih infekcij |
-
2009
- 2009-04-22 BR BRPI0911410A patent/BRPI0911410A2/pt not_active Application Discontinuation
- 2009-04-22 RS RS20150348A patent/RS54008B1/en unknown
- 2009-04-22 AP AP2010005439A patent/AP3076A/xx active
- 2009-04-22 CN CN2009801202188A patent/CN102046626A/zh active Pending
- 2009-04-22 KR KR1020107026265A patent/KR101645742B1/ko active IP Right Grant
- 2009-04-22 NO NO15155479A patent/NO2937350T3/no unknown
- 2009-04-22 US US12/428,176 patent/US8008264B2/en active Active
- 2009-04-22 HU HUE09734175A patent/HUE025528T2/en unknown
- 2009-04-22 BR BRPI0910455A patent/BRPI0910455B8/pt active IP Right Grant
- 2009-04-22 PL PL09734175T patent/PL2268642T3/pl unknown
- 2009-04-22 JP JP2011506435A patent/JP5425187B2/ja active Active
- 2009-04-22 EA EA201071128A patent/EA019883B1/ru not_active IP Right Cessation
- 2009-04-22 KR KR1020107026178A patent/KR101681559B1/ko active IP Right Grant
- 2009-04-22 MX MX2010011661A patent/MX2010011661A/es active IP Right Grant
- 2009-04-22 PL PL15155479T patent/PL2937350T3/pl unknown
- 2009-04-22 WO PCT/US2009/041447 patent/WO2009132135A1/en active Application Filing
- 2009-04-22 ES ES15155479.7T patent/ES2665272T3/es active Active
- 2009-04-22 EP EP15155479.7A patent/EP2937350B9/en active Active
- 2009-04-22 PT PT151554797T patent/PT2937350T/pt unknown
- 2009-04-22 EA EA201071170A patent/EA020659B1/ru unknown
- 2009-04-22 EP EP09734175.4A patent/EP2268642B1/en active Active
- 2009-04-22 SI SI200930503T patent/SI2280973T1/sl unknown
- 2009-04-22 ES ES09735162T patent/ES2398684T3/es active Active
- 2009-04-22 DK DK09734175.4T patent/DK2268642T3/en active
- 2009-04-22 KR KR1020167033059A patent/KR101856404B1/ko active IP Right Grant
- 2009-04-22 NZ NZ588400A patent/NZ588400A/xx unknown
- 2009-04-22 NZ NZ588670A patent/NZ588670A/xx not_active IP Right Cessation
- 2009-04-22 CA CA2722177A patent/CA2722177C/en active Active
- 2009-04-22 WO PCT/US2009/041432 patent/WO2009132123A1/en active Application Filing
- 2009-04-22 DK DK09735162.1T patent/DK2280973T3/da active
- 2009-04-22 ME MEP-2018-95A patent/ME03089B/me unknown
- 2009-04-22 JP JP2011506429A patent/JP5425186B2/ja active Active
- 2009-04-22 SI SI200931823T patent/SI2937350T1/en unknown
- 2009-04-22 CA CA2722084A patent/CA2722084C/en active Active
- 2009-04-22 SI SI200931153T patent/SI2268642T1/sl unknown
- 2009-04-22 US US12/428,234 patent/US8012941B2/en active Active
- 2009-04-22 PL PL09735162T patent/PL2280973T3/pl unknown
- 2009-04-22 CN CN200980114224.2A patent/CN102015714B/zh active Active
- 2009-04-22 TW TW102115415A patent/TW201334784A/zh unknown
- 2009-04-22 DK DK15155479.7T patent/DK2937350T3/en active
- 2009-04-22 MX MX2010011659A patent/MX2010011659A/es active IP Right Grant
- 2009-04-22 AP AP2010005414A patent/AP3237A/xx active
- 2009-04-22 PT PT97351621T patent/PT2280973E/pt unknown
- 2009-04-22 AR ARP090101420A patent/AR071395A1/es active IP Right Grant
- 2009-04-22 CN CN201410408008.1A patent/CN104262345B/zh active Active
- 2009-04-22 AU AU2009240642A patent/AU2009240642B2/en active Active
- 2009-04-22 PT PT97341754T patent/PT2268642E/pt unknown
- 2009-04-22 AU AU2009240630A patent/AU2009240630B2/en active Active
- 2009-04-22 HU HUE15155479A patent/HUE038946T2/hu unknown
- 2009-04-22 ES ES09734175.4T patent/ES2536193T3/es active Active
- 2009-04-22 RS RS20180408A patent/RS57092B1/sr unknown
- 2009-04-22 EP EP09735162A patent/EP2280973B1/en active Active
- 2009-04-22 TW TW098113324A patent/TWI401084B/zh active
- 2009-04-22 LT LTEP15155479.7T patent/LT2937350T/lt unknown
-
2010
- 2010-09-30 CO CO10121513A patent/CO6321235A2/es not_active Application Discontinuation
- 2010-10-06 IL IL208515A patent/IL208515A/en active IP Right Grant
- 2010-10-14 IL IL208701A patent/IL208701A/en active IP Right Grant
- 2010-10-22 CO CO10131479A patent/CO6300958A2/es not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07713A patent/ZA201007713B/en unknown
- 2010-11-09 ZA ZA2010/08008A patent/ZA201008008B/en unknown
- 2010-11-15 EC EC2010010609A patent/ECSP10010609A/es unknown
- 2010-11-19 EC EC2010010618A patent/ECSP10010618A/es unknown
-
2011
- 2011-07-05 HK HK11106883.4A patent/HK1152709A1/xx unknown
- 2011-08-02 US US13/196,117 patent/US8318682B2/en active Active
- 2011-08-09 HK HK11108347.0A patent/HK1154010A1/xx unknown
-
2012
- 2012-10-11 US US13/649,511 patent/US8853171B2/en not_active Ceased
-
2013
- 2013-01-21 HR HRP20130048AT patent/HRP20130048T1/hr unknown
- 2013-02-08 CY CY20131100119T patent/CY1113647T1/el unknown
- 2013-10-21 JP JP2013218129A patent/JP2014040471A/ja not_active Withdrawn
- 2013-10-21 JP JP2013218139A patent/JP2014012739A/ja not_active Withdrawn
-
2015
- 2015-03-30 HR HRP20150359TT patent/HRP20150359T1/hr unknown
- 2015-05-11 CY CY20151100412T patent/CY1116425T1/el unknown
-
2016
- 2016-04-27 HK HK16104808.6A patent/HK1216750A1/zh unknown
- 2016-10-07 US US15/288,271 patent/USRE46762E1/en active Active
-
2018
- 2018-04-04 CY CY20181100377T patent/CY1120366T1/el unknown
- 2018-04-10 HR HRP20180572TT patent/HRP20180572T1/hr unknown
-
2020
- 2020-12-17 LU LU00193C patent/LUC00193I2/en unknown
- 2020-12-18 LT LTPA2020539C patent/LTC2937350I2/lt unknown
- 2020-12-18 CY CY2020044C patent/CY2020044I1/el unknown
- 2020-12-18 HU HUS2000055C patent/HUS2000055I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2000055I1 (hu) | 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre | |
HRP20170197T1 (hr) | 2' -fluoro supstituirani karba-nukleozidni analozi za antiviralno liječenje | |
AP2922A (en) | Carbra-nucleoside analogs for antiviral treatment | |
AP3699A (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
TH0901001785B (th) | สารคล้ายคาร์บา-นิวคลิโอไซด์ที่ถูกแทนที่ที่ตำแหน่ง 1' สำหรับการบำบัดต้านไวรัส |